6.42
0.28 (4.56%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看跌 |
| Biotechnology (全球的) | 混合的 | 看跌 | |
| 股票 | Karyopharm Therapeutics Inc. | 看涨 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 3.5 |
| 内部交易活动 | -3.0 |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 0.5 |
| 平均 | 0.30 |
|
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 6.86% |
| 机构持股比例 | 48.43% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 56.00 (HC Wainwright & Co., 772.27%) | 购买 |
| 中 | 54.00 (741.12%) | |
| 低 | 3.00 (RBC Capital, -53.27%) | 购买 |
| 平均值 | 37.67 (486.76%) | |
| 总计 | 3 购买 | |
| 平均价格@调整类型 | 8.74 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Baird | 03 Mar 2025 | 54.00 (741.12%) | 购买 | 7.25 |
| HC Wainwright & Co. | 26 Feb 2025 | 56.00 (772.27%) | 购买 | 9.83 |
| 20 Feb 2025 | 7.00 (9.03%) | 购买 | 9.15 | |
| RBC Capital | 20 Feb 2025 | 3.00 (-53.27%) | 购买 | 9.15 |
| 10 Feb 2025 | 3.00 (-53.27%) | 购买 | 9.35 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合